Publications by authors named "Amalia Bonano-Rios"
Article Synopsis
- Next-generation sequencing (NGS) has revealed numerous genetic mutations that are critical for understanding cancer, particularly focusing on isocitrate dehydrogenase (IDH) enzymes.
- IDH exists in different forms (IDH1 in the cytosol and IDH2/IDH3 in mitochondria) and is crucial for metabolic processes such as converting isocitrate into α-ketoglutarate, affecting cellular functions like gene regulation and tissue health.
- Mutations in the IDH genes are linked to several cancers, including gliomas and acute myeloid leukemia, prompting exploration of IDH inhibitors as potential therapeutic options.
The dysregulation of the phosphatidylinositol-3-kinase (PI3K) pathway can lead to uncontrolled cellular growth and tumorigenesis. Targeting PI3K and its downstream substrates has been shown to be effective in preclinical studies and phase III trials with the approval of several PI3K pathway inhibitors by the Food and Drug Administration (FDA) over the past decade. However, the limited clinical efficacy of these inhibitors, intolerable toxicities, and acquired resistances limit the clinical application of PI3K inhibitors.
View Article and Find Full Text PDF